Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation
Genentech is conducting a first-in-human Phase I/II study of GDC-7035 targeting KRAS G12D mutations in advanced solid tumors.
Therapeutic Area
Therapeutic area intelligence for KRAS Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.